Literature DB >> 32354958

Debulking Surgery for Moderately Differentiated Neuroendocrine Gastric Carcinoma - A Case Report and Literature Review.

Nicolae Bacalbasa1,2,3, Iuliana Halmaciu4, Ciprian Bolca5, Adrian Neacsu1,6, Dragos Cretoiu1,7, Cristian Balalau1,8, Camelia Diaconu1,9, Laura Iliescu1,10, Alexandru Filipescu1,11, Cora Pop1,9, Irina Balescu12.   

Abstract

BACKGROUND/AIM: Gastroenteropancreatic neuro-endocrine carcinomas represent poorly differentiated neoplasms with a high capacity of spreading inducing the development of distant metastases. In such cases debulking surgery seems to offer a good chance for survival especially in well and moderately differentiated lesions. The aim of this study was to report the case of a 48-year-old patient submitted to surgery for moderately differentiated neuroendocrine gastric carcinoma with distant metastases. CASE REPORT: The patient was initially investigated for hematemesis and weight loss and was diagnosed with a lesser curvature gastric tumor in association with liver and peritoneal metastases. Due to the extent of the disease, the patient was initially submitted to neoadjuvant chemotherapy followed by surgery with radical intent. At the time of surgery subtotal gastrectomy en bloc with total omentectomy, peritonectomy, cholecystectomy and atypical liver resection were performed. Moreover, the two ovaries presented large tumoral masses so total hysterectomy with bilateral adnexectomy was performed. The histopathological studies confirmed the presence of a moderately differentiated neuroendocrine gastric carcinoma with negative resection margins.
CONCLUSION: Multiple visceral resections might be needed in order to maximize the debulking effort in metastatic gastric neuroendocrine carcinomas. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Krukenberg tumors; Neuroendocrine carcinoma; debulking surgery; liver metastases

Mesh:

Year:  2020        PMID: 32354958      PMCID: PMC7279793          DOI: 10.21873/invivo.11941

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  21 in total

1.  ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors.

Authors:  Marianne Pavel; Ashley Grossman; Rudolf Arnold; Aurel Perren; Gregory Kaltsas; Thomas Steinmüller; Wouter de Herder; George Nikou; Ursula Plöckinger; Jose Manuel Lopes; Hironobu Sasano; John Buscombe; Peter Lind; Dermot O'Toole; Kjell Oberg
Journal:  Neuroendocrinology       Date:  2010-05-06       Impact factor: 4.914

2.  Survival and Complication Rates of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma Treated Exclusively With Targeted Therapy: A Combined Population-based Analysis.

Authors:  Carlotta Palumbo; Angela Pecoraro; Sophie Knipper; Giuseppe Rosiello; Zhe Tian; Shahrokh F Shariat; Claudio Simeone; Alberto Briganti; Fred Saad; Alfredo Berruti; Alessandro Antonelli; Pierre I Karakiewicz
Journal:  Anticancer Res       Date:  2019-08       Impact factor: 2.480

Review 3.  Antitumor effects of somatostatin analogs in neuroendocrine tumors.

Authors:  Lucas Sidéris; Pierre Dubé; Anja Rinke
Journal:  Oncologist       Date:  2012-05-24

4.  Typical carcinoids and neuroendocrine carcinomas of the stomach: differing clinical courses and prognoses.

Authors:  Beom Su Kim; Sung Tae Oh; Jeong Hwan Yook; Kab Choong Kim; Min Gyu Kim; Jun Won Jeong; Byung Sik Kim
Journal:  Am J Surg       Date:  2010-04-10       Impact factor: 2.565

5.  Gastric carcinoids: a temporal increase with proton pump introduction.

Authors:  N Hodgson; L G Koniaris; A S Livingstone; D Franceschi
Journal:  Surg Endosc       Date:  2005-10-05       Impact factor: 4.584

6.  Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management.

Authors:  Irvin M Modlin; Steven F Moss; Kjell Oberg; Robert Padbury; Rodney J Hicks; Bjorn I Gustafsson; Nicholas A Wright; Mark Kidd
Journal:  Med J Aust       Date:  2010-07-05       Impact factor: 7.738

Review 7.  Gastric and duodenal neuroendocrine tumours.

Authors:  Dermot O'Toole; Gianfranco Delle Fave; Robert T Jensen
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-12       Impact factor: 3.043

8.  Relevant infrastructural alterations in a pancreatic neuroendocrine tumor: an insulinoma case.

Authors:  Gabriel-Valeriu Mirancea; Ana-Maria Moroşanu; Simona Carniciu; Simona Dima; Nicolae Bacalbaşa; Irinel Popescu; Constantin Ionescu-Tîrgovişte; Nicolae Mirancea
Journal:  Rom J Morphol Embryol       Date:  2014       Impact factor: 1.033

9.  Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.

Authors:  A Ahmed; G Turner; B King; L Jones; D Culliford; D McCance; J Ardill; B T Johnston; G Poston; M Rees; M Buxton-Thomas; M Caplin; J K Ramage
Journal:  Endocr Relat Cancer       Date:  2009-05-20       Impact factor: 5.678

10.  Gastric neuroendocrine neoplasm with late liver metastasis.

Authors:  Bernardo Marques; Raquel G Martins; Guilherme Tralhão; Joana Couto; Sandra Saraiva; Henrique Ferrão; João Ribeiro; Jacinta Santos; Teresa Martins; Ana Teresa Cadime; Fernando Rodrigues
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.